newsfilter
← Latest News
Business Wire·

Aptinyx Reports Second Quarter 2022 Financial Results and Recent Highlights

Company expects to report results from Phase 2b study of NYX-2925 in fibromyalgia in August Data from Phase 2 study of NYX-458 in cognitive impairment expected in 1Q 2023 IND cleared for NIH grant-funded evaluation of NYX-783 in opioid use disor